This is a prospective, exploratory, randomised clinical trial. Patients with diagnosed cancer that are to be treated with 5-fluorouracil (5-FU) will be randomised into standard oncological treatment or a cardiological assessment prior to the 5-FU treatment. The investigators hypothesize that aggressive management of ischemic risk factors in asymptomatic patients will reduce the number of hospitalisations and investigations for acute coronary syndrome during and after 5-FU treatment and that patients with high coronary artery calcium scores are more likely to experience chest pain during the treatment with 5-FU.

Inclusion Criteria:

• Histologically verified cancer
• First-time treatment with 5-FU/Capecitabine
• Expected remaining lifetime > 6 months
• Informed consent

Exclusion Criteria:

• Known ischemic heart disease
• Ischemia-suspicious symptoms prior to 5-FU treatment
• Ischemia-suspicious ECG-changes prior to 5-FU treatment